Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Treatment choices for acute myelogenous leukemia (AML) patients resistant to conventional chemotherapies are limited and novel therapeutic agents are needed. IL3 receptor alpha (IL3Rα, or CD123) is expressed on the majority of AML blasts, and there is evidence that its expression is increased on leukemic relative to normal hematopoietic stem cells, which makes it an attractive target for antibody-based therapy. Here, we report the generation and preclinical characterization of SGN-CD123A, an antibody–drug conjugate using the pyrrolobenzodiazepine dimer (PBD) linker and a humanized CD123 antibody with engineered cysteines for site-specific conjugation. Mechanistically, SGN-CD123A induces activation of DNA damage response pathways, cell-cycle changes, and apoptosis in AML cells. In vitro, SGN-CD123A–mediated potent cytotoxicity of 11/12 CD123+ AML cell lines and 20/23 primary samples from AML patients, including those with unfavorable cytogenetic profiles or FLT3 mutations. In vivo, SGN-CD123A treatment led to AML eradication in a disseminated disease model, remission in a subcutaneous xenograft model, and significant growth delay in a multidrug resistance xenograft model. Moreover, SGN-CD123A also resulted in durable complete remission of a patient-derived xenograft AML model. When combined with a FLT3 inhibitor quizartinib, SGN-CD123A enhanced the activity of quizartinib against two FLT3-mutated xenograft models. Overall, these data demonstrate that SGN-CD123A is a potent antileukemic agent, supporting an ongoing trial to evaluate its safety and efficacy in AML patients (NCT02848248). Mol Cancer Ther; 17(2); 554–64. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA Damage Sensing by the ATM and ATR Kinases
Marechal, A., & Zou, L. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012716 · Cited by 1,514
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
Townsend, E. C., Murakami, M. A., Christodoulou, A., Christie, A. L., Köster, J., DeSouza, T. A., Morgan, E. A., Kallgren, S. P., Liu, H., Wu, S.-C., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.008 · Cited by 295 · cited 1×
“Patient-derived xenograft models are thought to better mimic the physiology of AML patients, and thus better predict the clinical performance of drugs (25).”
Background
Cited by
Cancer stem cells—Origins and biomarkers: Perspectives for targeted personalized therapies
Walcher, L., Kistenmacher, A.-K., Suo, H., Kitte, R., Dluczek, S., Strauß, A., Blaudszun, A.-R., Yevsa, T., Fricke, S., & Kossatz-Boehlert, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01280 · Cited by 1,007
Site-selective modification strategies in antibody–drug conjugates
Walsh, S. J., Bargh, J. D., Dannheim, F. M., Hanby, A. R., Seki, H., Counsell, A. J., Ou, X., Fowler, E., Ashman, N., Takada, Y., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00310g · Cited by 461
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023) · Cancers · doi:10.3390/cancers15030713 · Cited by 441
Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy
Hartley, J. A. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1776255 · Cited by 109
“Impressive pre-clinical data with three other talirine-containing ADCs, SGN-CD19B [29], SGN-CD123A [30] and SGN-CD352A [31], led to phase 1 trials being initiated in B-cell NHL, AML and multiple myeloma, respectively.”
Background
Metadata
- Authors
- Li, F., Sutherland, M. K., Yu, C., Walter, R. B., Westendorf, L., Valliere-Douglass, J., Pan, L., Cronkite, A., Sussman, D., Klussman, K., Ulrich, M., Anderson, M. E., Stone, I. J., Zeng, W., Jonas, M., Lewis, T. S., Goswami, M., Wang, S. A., Senter, P. D., Law, C.-L., Feldman, E. J., & Benjamin, D. R.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2018-02-01
- Volume
- 17
- Issue
- 2
- Pages
- 554-564
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2768799228
- Cited by
- 102
- References
- 2
- FWCI
- 9.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia. https://app.cochat.ai/papers/10.1158/1535-7163.mct-17-0742
- The paper
- Li, F., Sutherland, M. K., Yu, C., Walter, R. B., Westendorf, L., Valliere-Douglass, J., Pan, L., Cronkite, A., Sussman, D., Klussman, K., Ulrich, M., Anderson, M. E., Stone, I. J., Zeng, W., Jonas, M., Lewis, T. S., Goswami, M., Wang, S. A., Senter, P. D., . . . Benjamin, D. R. (2018). Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-17-0742
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.